TFA
VVOS icon

Toth Financial Advisory’s Vivos Therapeutics VVOS Stock Holding History

Toth Financial Advisory’s Portfolio VVOS Stock Details VVOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-8
Closed -$69 – 899
2023
Q1 		$69 Hold
8
– – ﹤0.01% 802
2022
Q4 		$80 Hold
8
– – ﹤0.01% 704
2022
Q3 		$0 Hold
8
– – ﹤0.01% 809
2022
Q2 		$0 Hold
8
– – ﹤0.01% 778
2022
Q1 		$1K Hold
8
– – ﹤0.01% 694
2021
Q4 		$0 Hold
8
– – ﹤0.01% 824
2021
Q3 		$1K Hold
8
– – ﹤0.01% 730
2021
Q2 		$1K Buy
+8
New +$1.3K ﹤0.01% 669

Other funds holding VVOS

SWIG
Strategic Wealth Investment Group Louisville, Kentucky $788M AUM 14.6% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
GGI
Godsey & Gibb Inc Richmond, Virginia $1.22B AUM 27.93% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Credit Agricole
Credit Agricole Montrouge Cedex, France $38.1B AUM
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AF
Apexium Financial Dallas, Texas $2.06B AUM 15.96% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

Toth Financial Advisory's VVOS Position: Q2 2023 in Review

Toth Financial Advisory sold out of Vivos Therapeutics (VVOS) in Q2 2023, closing a stake of 8 shares — an estimated $69 sold.

Toth Financial Advisory first reported a position in VVOS in Q2 2021 and held it in 8 quarters. The position peaked at $1K in Q1 2022. 30 funds tracked by Wall St. Rank hold VVOS as of Q2 2023.

  • Toth Financial Advisory reported no remaining Vivos Therapeutics position as of Q2 2023 after selling out during the quarter.
  • Toth Financial Advisory sold 8 Vivos Therapeutics shares in Q2 2023, an estimated $69.
  • Toth Financial Advisory first reported a position in Vivos Therapeutics in Q2 2021 and held it in 8 quarters.
  • Toth Financial Advisory's Vivos Therapeutics position peaked at $1K in Q1 2022.
  • 30 funds tracked by Wall St. Rank held Vivos Therapeutics as of Q2 2023.

Based on Toth Financial Advisory's 13F filing for Q2 2023, filed 24 Jul 2023.